MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 574859 | Name: Ro-51
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ro-51 is a cell permeable dual P2X3 and P2X2/3 antagonist.

Chemical Structure

Ro-51
Ro-51
CAS#1050670-85-3

Theoretical Analysis

MedKoo Cat#: 574859

Name: Ro-51

CAS#: 1050670-85-3

Chemical Formula: C17H23IN4O4

Exact Mass: 474.0764

Molecular Weight: 474.30

Elemental Analysis: C, 43.05; H, 4.89; I, 26.76; N, 11.81; O, 13.49

Price and Availability

Size Price Availability Quantity
10mg USD 550.00 2 Weeks
50mg USD 1,750.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Ro-51; Ro 51; Ro51
IUPAC/Chemical Name
2-((4-amino-5-(5-iodo-2-isopropyl-4-methoxyphenoxy)pyrimidin-2-yl)amino)propane-1,3-diol
InChi Key
PAYROHWFGZADBR-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H23IN4O4/c1-9(2)11-4-14(25-3)12(18)5-13(11)26-15-6-20-17(22-16(15)19)21-10(7-23)8-24/h4-6,9-10,23-24H,7-8H2,1-3H3,(H3,19,20,21,22)
SMILES Code
NC1=NC(NC(CO)CO)=NC=C1OC2=C(C(C)C)C=C(OC)C(I)=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Certificate of Analysis
View CoA: current batch, Lot#R22N03D01
Safety Data Sheet (SDS)
View Safety Data Sheet (SDS)
Instruction
View handling instruction
Biological target:
Ro-51 has IC50 values of 2 and 5 nM for rP2X3 and hP2X2/3 respectively). Ro-51 is selective for P2X3 and P2X2/3 over other P2X receptors (IC50 values are > 10 μM for P2X1, P2X2, P2X4, P2X5, and P2X7).
In vitro activity:
This article presents the discovery of Ro-51. Reference: Bioorg Med Chem Lett. 2009 Mar 15;19(6):1632-5. https://pubmed.ncbi.nlm.nih.gov/19231178/
In vivo activity:
To be determined

Preparing Stock Solutions

The following data is based on the product molecular weight 474.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Jahangir A, Alam M, Carter DS, Dillon MP, Bois DJ, Ford AP, Gever JR, Lin C, Wagner PJ, Zhai Y, Zira J. Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1632-5. doi: 10.1016/j.bmcl.2009.01.097. Epub 2009 Feb 4. PMID: 19231178.
In vitro protocol:
1. Jahangir A, Alam M, Carter DS, Dillon MP, Bois DJ, Ford AP, Gever JR, Lin C, Wagner PJ, Zhai Y, Zira J. Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1632-5. doi: 10.1016/j.bmcl.2009.01.097. Epub 2009 Feb 4. PMID: 19231178.
In vivo protocol:
To be determined
1: Park YW, Yoon JH, Shin KH, Cho YJ, Yun JH, Han WH, Hong MH, Kang DG, Kim HY. Enhancing Stiffness and Oil Resistance of Fluorosilicone Rubber Composites through Untreated Cellulose Reinforcement. Polymers (Basel). 2023 Nov 22;15(23):4489. doi: 10.3390/polym15234489. PMID: 38231938; PMCID: PMC10707869. 2: Kim J, Lee DC, Kim HS. Design optimization of a flexure spring used in small- sized ultra-precise optical instrument. Heliyon. 2023 Nov 22;9(12):e22560. doi: 10.1016/j.heliyon.2023.e22560. PMID: 38107309; PMCID: PMC10724568. 3: Kim HT, Lee JH, Lee JW, Lee BH, Jeon CH. Effect of Operating Conditions on the Gasification of Pet-Coke Water Slurry in an Entrained-Flow Gasifier Simulation. ACS Omega. 2023 Nov 21;8(48):45933-45941. doi: 10.1021/acsomega.3c06688. PMID: 38075827; PMCID: PMC10702294. 4: Yoo HK, Byun HG, Caprioli F, Fumery M, Peyrin-Biroulet L, Sreedhar S, Potter J, Jang M. Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries. BMC Health Serv Res. 2022 Nov 4;22(1):1319. doi: 10.1186/s12913-022-08683-y. PMID: 36333704; PMCID: PMC9636776. 5: Shin YK, Han WY, Kim SJ, Kim KW, Roh JW, Lee JB, Oh JS, Astier A. Investigation of the Physicochemical and Biological Stability of the Adalimumab Biosimilar CT-P17. Adv Ther. 2021 Nov;38(11):5609-5622. doi: 10.1007/s12325-021-01929-x. Epub 2021 Oct 7. PMID: 34618346. 6: Byun HG, Jang M, Yoo HK, Potter J, Kwon TS. Budget Impact Analysis of the Introduction of Subcutaneous Infliximab (CT-P13 SC) for the Treatment of Rheumatoid Arthritis in the United Kingdom. Appl Health Econ Health Policy. 2021 Sep;19(5):735-745. doi: 10.1007/s40258-021-00673-1. Epub 2021 Aug 12. PMID: 34383287. 7: Jang M, Simoens S, Kwon T. Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets. BioDrugs. 2021 Jan;35(1):89-101. doi: 10.1007/s40259-020-00461-8. Epub 2020 Dec 24. PMID: 33368051; PMCID: PMC7803676. 8: Krause S, Lacana E, Welch J, Shapiro M, Downey C, Chung J, Zhou Q, Van Der Plas M, Depatie C, Ingram B, Srebalus-Barnes C, Polozova A, Rellahan B, Choi D, Burdick R, Stangler T, Shacter E. PDA Biosimilars Workshop Report (September 27-28, 2018)-Getting It Right the First Time for Biosimilar Marketing Applications. PDA J Pharm Sci Technol. 2019 Jul-Aug;73(4):401-416. doi: 10.5731/pdajpst.2019.010215. Epub 2019 Apr 19. PMID: 31004040. 9: Kim SJ, Kim KW, Shin YK, Kwon JW, Kang HY, Park YA, Shin JY, Kim SY, Han WY. In-Use Stability of the Rituximab Biosimilar CT-P10 (Truxima®) Following Preparation for Intravenous Infusion and Storage. BioDrugs. 2019 Apr;33(2):221-228. doi: 10.1007/s40259-019-00336-7. PMID: 30747341. 10: Moon KH. Screening of Genetic Factor in the Interaction Between Periodontitis and Metabolic Traits Using Candidate Gene Association Study (CGAS). Biochem Genet. 2019 Jun;57(3):466-474. doi: 10.1007/s10528-018-9899-9. Epub 2018 Dec 13. PMID: 30547318; PMCID: PMC6556154. 11: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Vemurafenib. 2018 Dec 3. PMID: 29999925. 12: Patra JK, Kim ES, Oh K, Kim HJ, Dhakal R, Kim Y, Baek KH. Bactericidal effect of extracts and metabolites of Robinia pseudoacacia L. on Streptococcus mutans and Porphyromonas gingivalis causing dental plaque and periodontal inflammatory diseases. Molecules. 2015 Apr 8;20(4):6128-39. doi: 10.3390/molecules20046128. PMID: 25856062; PMCID: PMC6272705. 13: Serrano A, Mo G, Grant R, Paré M, O'Donnell D, Yu XH, Tomaszewski MJ, Perkins MN, Séguéla P, Cao CQ. Differential expression and pharmacology of native P2X receptors in rat and primate sensory neurons. J Neurosci. 2012 Aug 22;32(34):11890-6. doi: 10.1523/JNEUROSCI.0698-12.2012. PMID: 22915129; PMCID: PMC6703778. 14: Jahangir A, Alam M, Carter DS, Dillon MP, Bois DJ, Ford AP, Gever JR, Lin C, Wagner PJ, Zhai Y, Zira J. Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1632-5. doi: 10.1016/j.bmcl.2009.01.097. Epub 2009 Feb 4. PMID: 19231178. 15: Miwa H, Sasaki M, Furuta T, Koike T, Habu Y, Ito M, Fujiwara Y, Wada T, Nagahara A, Hongo M, Chiba T, Kinoshita Y; ACID-RELATED SYMPTOM (ARS) RESEARCH GROUP. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan. Aliment Pharmacol Ther. 2007 Jul 1;26(1):69-77. doi: 10.1111/j.1365-2036.2007.03350.x. PMID: 17555423.